NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY

被引：0
|
作者：
Kantarjian, H. [1 ]
Giles, F. G. [2 ]
Bhalla, K. N. P. [3 ]
Pinilla, J. [4 ]
Larson, R. A. [5 ]
Gattermann, N. [6 ]
Ottmann, O. G. [7 ]
Wang, J. [8 ]
Gallagher, N. J. [9 ]
Baccarani, M. [10 ]
Le Coutre, P. D. [11 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] San Antonios Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX USA
[3] Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA
[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[5] Univ Chicago, Chicago, IL 60637 USA
[6] Univ Dusseldorf, Dusseldorf, Germany
[7] Med Klin 3, Frankfurt, Germany
[8] Novartis Pharmaceut, Florham Pk, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
[10] Univ Bologna, Bologna, Italy
[11] Univ Med Berlin, Berlin, Germany
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0627
引用
收藏
页码：254 / 255
页数：2
相关论文
共 50 条
  • [1] Nilotinib in chronic myeloid leukaemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: follow-up results of a phase 2 study
    Clark, R.
    le Coutre, P.
    Giles, F. J.
    Hocchaus, A.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    Kantarjian, H. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 40 - 40
  • [2] Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study
    Kantarjian, Hagop M.
    Giles, Francis
    Bhalla, Kapil N.
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Haque, Ariful
    Gallagher, Neil J.
    Baccarani, Michele
    le Coutre, Philipp D.
    BLOOD, 2008, 112 (11) : 1112 - 1112
  • [3] Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
    Kantarjian, H.
    Giles, F.
    Bhalla, K.
    Pinilla, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Gallagher, N. J.
    Baccarani, M.
    leCoutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN ACCELERATED PHASE (CML-AP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY
    Hochhaus, A.
    Giles, F.
    Apperely, J.
    Ossenkoppele, G.
    Wang, J.
    Gallagher, N. J.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H.
    Le Coutre, P. D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 256 - 256
  • [5] Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up
    Larson, R. A.
    Kim, D.
    Rosti, G.
    Stenke, L.
    Pasquini, R.
    Hoenekopp, A.
    Blakesley, R. E.
    Gallagher, N. J.
    Hochhaus, A.
    Hughes, T. P.
    Saglio, G.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
    Kantarjian, Hagop M.
    Giles, Francis J.
    Bhalla, Kapil N.
    Pinilla-Ibarz, Javier
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Hochhaus, Andreas
    Radich, Jerald P.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Martinelli, Giovanni
    Kim, Dong-Wook
    Shou, Yaping
    Gallagher, Neil J.
    Blakesley, Rick
    Baccarani, Michele
    Cortes, Jorge
    le Coutre, Philipp D.
    BLOOD, 2011, 117 (04) : 1141 - 1145
  • [7] Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
    le Coutre, P. D.
    Giles, F. J.
    Hochhaus, A.
    Apperley, J. F.
    Ossenkoppele, G. J.
    Blakesley, R.
    Shou, Y.
    Gallagher, N. J.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H. M.
    LEUKEMIA, 2012, 26 (06) : 1189 - 1194
  • [8] Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
    P D le Coutre
    F J Giles
    A Hochhaus
    J F Apperley
    G J Ossenkoppele
    R Blakesley
    Y Shou
    N J Gallagher
    M Baccarani
    J Cortes
    H M Kantarjian
    Leukemia, 2012, 26 : 1189 - 1194
  • [9] Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study
    le Coutre, Philipp D.
    Giles, Francis J.
    Pinilla-Ibarz, Javier
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Hochhaus, Andreas
    Radich, Jerald P.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Martinelli, Giovanni
    Kim, Dong-Wook
    Branford, Susan
    Mueller, Martin C.
    Shou, Yaping
    Novick, Steven
    Fan, Xiaolin
    Cortes, Jorge E.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1610 - 1610
  • [10] Efficacy and Safety of Nilotinib in elderly patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance
    Ottmann, O. G.
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Bruemmendorf, T. H.
    Kindler, T.
    Duyster, J.
    Al-Ali, H.
    Lipton, J.
    Wang, J.
    Yang, M.
    Szczudlo, T.
    Giles, F.
    ONKOLOGIE, 2010, 33 : 138 - 138
12345